Comprehensive Forecast: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share, Growth, and Opportunities Through 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Large Is the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Expected to Be in 2029?
The market size for the treatment of chronic obstructive pulmonary disease (copd) has been experiencing steady growth over the recent years. The growth will escalate from $20.84 billion in 2024 to $21.73 billion in 2025, showcasing a compound annual growth rate (CAGR) of 4.3%. The growth during the historical period is tied to the smoking epidemic and tobacco usage, advancements in inhalation treatment methods, heightened awareness programs, early diagnostic procedures, government-supported initiatives for respiratory health, and continuous research and development in the field of pulmonology.
Expectations are high for substantial expansion in the chronic obstructive pulmonary disease (COPD) treatment market over the coming years. The market is predicted to increase to $27.22 billion in 2029, with a compound annual growth rate (CAGR) of 5.8%. The predicted growth during this period can be ascribed to elements such as customized medication and biomarker studies, biologic treatments and targeted engagements, concerns over air quality and external factors, global campaigns aimed at quitting smoking, and partnerships formed for drug development. Key trends that are forecasted during this period encompass digital health solutions aimed at managing COPD, biologic treatments for COPD, the rise of customized medication, combination therapies and inhalers, early detection and intervention, along with pulmonary rehabilitation programs.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10054&type=smp
What Are The Contributors To Demand In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
The rise in lung disease rates is anticipated to drive the chronic obstructive pulmonary disease (COPD) treatment market’s expansion. Lung disease hampers the lungs, hindering their normal operations. The most widespread lung ailments include asthma, COPD, and lung cancer. The main purpose of chronic obstructive pulmonary disease (COPD) treatment is to regulate lung disease, slow down its progression, control its symptoms, and prevent lung damage through the use of inhalers and medicines. For example, as per the global initiative for Chronic obstructive lung disease (GOLD), a non-profit organization based in the US, in September 2022, it was reported that chronic obstructive pulmonary disease (COPD) results in the death of 3.2 million people annually and affects an estimated 200 million people worldwide. Moreover, in 2022, asthma affected 262 million people internationally. These figures are predicted to increase in the coming years. Additionally, according to the LUNGevity Foundation, a US non-profit institution, in 2023, lung cancer will cause the death of 127,000 Americans each year. Hence, the growing occurrence of lung disease is stimulating the enhancement of the chronic obstructive pulmonary disease (COPD) treatment market.
What Segmentation Categories Are Included In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis?
The chronic obstructive pulmonary disease (copd) treatment market covered in this report is segmented –
1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS)
2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA)
3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids
4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors
5) By Mucokinetics: Expectorants, Mucolytics
6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents
What Upcoming Trends Are Expected To Impact The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Globally?
A key trend emerging in the chronic obstructive pulmonary disease (COPD) treatment market is product innovation. Major firms active in the COPD treatment landscape are striving to design innovative products in an effort to maintain their market standing. For example, in April 2022, UK-based pharmaceutical and biotech firm GlaxoSmithKline plc (GSK) introduced Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) in India. This product, the first of its kind as a single-inhaler triple treatment (SITT) for COPD, is designed for patients 18 years and above. Trelegy Ellipta operates in a similar way to natural corticosteroid hormones, targeting specific immune cells and reducing their activity. Moreover, it aids in alleviating lung airway inflammation, thereby easing the act of breathing.
Who Are The Top-Ranked Companies In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Today?
Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market include Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Abbott Laboratories, Chiesi Farmaceutici S.p.A, Mylan N.V., Orion Corporation, Sunovion Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Circassia Group PLC, Kyowa Kirin Co. Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Alcon Laboratories Inc., Amgen Inc., Apotex Inc., Aurobindo Pharma Limited, Biocon Limited, Biogen Inc., Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals plc, Lupin Limited, Meda AB, Mundipharma International Limited, Pfizer Inc.
Get The Full Report Here:
How Is Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Adoption Varying Across Different Regions And Sectors?
North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2024.Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (COPD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10054&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
